Patients Clinical Trial

Recent News

08/07/2014
GI Dynamics to Present at the 34th Annual Canaccord Genuity Growth Conference
Read More

07/31/2014
Appendix 4C Quarterly Report Quarter ended 30 June 2014
Read More

07/30/2014
GI Dynamics Announces Launch of EndoBarrierĀ® Therapy Clinical Utility Study in France
Read More


EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE